Remdisivir for COVID-19 to be priced under Rs 5,000 in India
Cipla and Hetero Labs have received approval to sell generic versions of remdesivir, developed by Gilead Sciences Inc, in India
Indian pharmaceutical company Cipla Ltd has announced that its generic version of antiviral drug remdesivir for use in treating COVID-19 patients will be made available under Rs 5,000.
However, the company did not provide details on when the generic version called Cipremi, will be available.
Cipla and privately held Indian drugmaker Hetero Labs received approval to sell generic versions of remdesivir, developed by Gilead Sciences Inc, in the country on Sunday.
According to reports, remdesivir, which is administered via injection in hospitals, is the first treatment that show improvement in COVID-19 trials.
Countries like the United States, India and South Korea have approved the drug for emergency use in severely ill patients while Japan has given full approval for use of the drug.
Beximco Pharmaceuticals Ltd of Bangladesh was the first company in the world to introduce a generic version of remdesivir in May.